HERS II, 2002 error versus error

JAMA 2002;288:58-66  

error versus error in




Studied treatment
Control treatment



Patients
Group sizes 1156 / 1165
type of prevention (secondary prevention
diabetes (%)
hypertension (%)
hyperlipidemia (%)
BMI (kg/m²)
Hysterectomy (%)
Oophorectomy (%)



Blindness Inclusion period
Follow-up duration Centers
Lost to FU geographical localisation
Primary endpoint Design



EndpointX1N1X0N0TE95% CI CV events 228 1156 228 1165 1,01[0,82; 1,24] Cv death 62 1156 63 1165 0,99[0,69; 1,42] Coronary events (CHD) - 1156 - 1165 no data non fatal MI 61 1156 62 1165 0,99[0,69; 1,43] stroke 59 1156 55 1165 1,08[0,74; 1,58] venous thromboembolism 15 1156 11 1165 1,37[0,63; 3,00] PE 6 1156 2 1165 Out of scale3,02[0,61; 15,01] all cause death 131 1156 116 1165 1,14[0,87; 1,48]0,22,01,0


Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H, Vittinghoff E, Hunninghake D Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:58-66     [PMID: 12090863]   link to pdf  

 




Appears in following systematic reviews: